CSIMarket
 
Ventyx Biosciences Inc   (NASDAQ: VTYX)
Other Ticker:  
 
 
Price: $1.7300 $-0.06 -3.352%
Day's High: $1.82 Week Perf: -7.49 %
Day's Low: $ 1.71 30 Day Perf: -31.35 %
Volume (M): 1,305 52 Wk High: $ 11.48
Volume (M$): $ 2,257 52 Wk Avg: $3.29
Open: $1.79 52 Wk Low: $1.67



 Market Capitalization (Millions $) 122
 Shares Outstanding (Millions) 71
 Employees 77
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -153
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Ventyx Biosciences Inc
Ventyx Biosciences Inc. is a pharmaceutical company focused on the development of new treatments for a range of diseases including cancer, infectious diseases, and autoimmune disorders. The company was founded in 2013 and is headquartered in San Diego, California.

Ventyx Biosciences specializes in the development of innovative drugs that target specific molecular pathways involved in disease progression. The company has a strong research and development pipeline that includes both small molecule drugs and biologics.

One of the key areas of focus for Ventyx Biosciences is the development of drugs that target the PI3K/AKT/mTOR pathway, which is involved in a variety of diseases including cancer, cardiovascular disease, and neurodegeneration. The company has several candidates in preclinical and clinical development targeting this pathway, including VTX-01, which is being developed for the treatment of solid tumors.

In addition to its work on the PI3K/AKT/mTOR pathway, Ventyx Biosciences is also developing drugs that target the NF-kB signaling pathway, which is involved in inflammation and immune responses. The company's lead candidate in this area is VTX-02, which is being developed for the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis and psoriasis.

Ventyx Biosciences has a strong team of experienced scientists and executives with a track record of success in drug development. The company has also established collaborations with leading academic institutions and pharmaceutical companies to accelerate its research and development efforts.

Overall, Ventyx Biosciences is a promising biotech company with a strong pipeline of innovative drugs targeting diverse disease areas. The company is well-positioned to make a significant impact on the pharmaceutical industry in the coming years.


   Company Address: 12790 El Camino Real San Diego 92130 CA
   Company Phone Number: 593-4832   Stock Exchange / Ticker: NASDAQ VTYX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.24% 
ABT        0.48% 
BMY   -5.17%    
JNJ        0.82% 
MRK   -12.54%    
PFE   -1.76%    
• View Complete Report
   



Clinical Study

Advances in Gastrointestinal and Metabolic Therapies Insights from Ventyx Biosciences? Recent Clinical Trials and P...

Published Tue, Oct 15 2024 12:01 PM UTC

Abstract: Ventyx Biosciences has made significant strides in the development of novel therapeutic agents for gastrointestinal diseases, showcasing promising results from recent clinical trials for ulcerative colitis and Crohn s disease. Additionally, preclinical studies on a CNS-penetrant NLRP3 inhibitor exhibit potential in combating obesity and related metabolic dysfuncti...

Shares

Sanofis $27 Million Bet on Ventyx Biosciences Shines Spotlight on Groundbreaking CNS Inhibitor VTX3232,

Published Mon, Sep 23 2024 12:01 PM UTC

On September 6, 2024, Ventyx Biosciences, a forward-thinking biotechnology company focused on developing innovative therapeutics, announced a significant $27 million strategic investment from Sanofi, the global healthcare leader. This investment underscores the growing confidence in Ventyx s pioneering work, particularly their CNS-penetrant NLRP3 inhibitor, VTX3232. As part ...

Clinical Study

Ventyx Biosciences, a biotechnology company focused on developing innovative therapeutics, has ...

Published Fri, Sep 6 2024 12:01 PM UTC

Title : Ventyx Biosciences Advances Parkinson s Research with Phase 2a Trial of VTX3232:Ventyx Biosciences, a biotechnology company focused on developing innovative therapeutics, has officially announced the initiation of dosing in a Phase 2a clinical trial for its investigational drug, VTX3232. The trial aims to evaluate the safety, efficacy, and tolerability of VTX3232 in ...

Clinical Study

Ventyx Biosciences Faces Setback as VTX958 Trial Fails to Meet Primary Endpoint for Crohn?s Disease Treatment ...

Published Mon, Jul 29 2024 12:01 PM UTC

Phase 2 Trial of VTX958 Fails to Meet Primary Endpoint in Crohn?s Disease Patients: Implications for Ventyx BiosciencesIn the realm of gastroenterology and inflammatory bowel diseases, the importance of therapeutic options cannot be overstated, particularly in complex conditions such as Crohn s disease. Ventyx Biosciences recently announced the results of its Phase 2 trial...

Stocks on the Move

Analyzing the Underperformance of Ventyx Biosciences Inc Shares this Month

Published Sat, Jul 6 2024 12:17 PM UTC

Throughout the month, the shares of Ventyx Biosciences Inc have been trailing behind the performance of the overall market. This article aims to provide an analysis of the factors contributing to this underperformance. By examining relevant events and financial data, we will gain insights into the recent downward trend and explore potential reasons for this decline.Examinat...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com